Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Other: Questionnaire Administration
- Registration Number
- NCT02131584
- Lead Sponsor
- M.D. Anderson Cancer Center
- Brief Summary
This phase II trial studies how well ruxolitinib phosphate works in reducing fatigue in patients with chronic lymphocytic leukemia. Ruxolitinib phosphate may stop the growth of cancer cells by blocking a protein called Janus kinase (JAK) that is needed for cell growth and may also help control fatigue, decrease the size of lymph nodes and/or lower the number of chronic lymphocytic leukemia cells in the blood.
- Detailed Description
PRIMARY OBJECTIVE:
I. To estimate the reduction in fatigue as measured by the Brief Fatigue Inventory (BFI) of patients with chronic lymphocytic leukemia (CLL) who do not require anti-neoplastic therapy according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 recommendations.
SECONDARY OBJECTIVE:
I. To estimate the reduction in other symptoms using the M. D. Anderson Symptom Inventory (MDASI) and to assess disease burden and response by the IWCLL 2008 response criteria.
OUTLINE:
Patients receive ruxolitinib phosphate orally (PO) twice daily (BID) (approximately 12 hours apart) for up to 2 years in the absence of disease progression or unacceptable toxicity.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 10
- Subjects who are able to understand and sign an informed consent document
- Subjects must be diagnosed with CLL and do not meet the IWCLL criteria for treatment
- Patients may have been previously treated or previously untreated
- Symptomatic patients with a BFI symptom scale of 2 points or greater
- Subjects with hemoglobin values at the screening visit equal to or greater than 12.0 g/dL
- Subjects with a platelet count of at least 75 x 10^9/L at the screening visit
- Subjects with an absolute neutrophil count (ANC) of equal to or higher than 0.5 x 10^9/L at the screening visit
- Subjects must have discontinued all drugs used to treat CLL no later than day -30
- Subjects with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
-
Females who are pregnant or are currently breastfeeding
-
Subjects of childbearing potential who are unwilling to take appropriate precautions (throughout the study from screening, including 30 days after discontinuation of the study drug) to avoid becoming pregnant or fathering a child
-
Females of non-childbearing potential are defined as women who (a) are equal to or greater than 55 years of age with history of amenorrhea for 1 year, or (b) are surgically sterile for at least 3 months
-
For females of childbearing potential, or for males, appropriate precautions are those that are at least 99% effective in preventing the occurrence of pregnancy; these methods should be communicated to the subjects and their understanding confirmed:
- Complete abstinence from sexual intercourse
- Double barrier methods
- Condom with spermicide in conjunction with use of an intrauterine device (IUD)
- Condom with spermicide in conjunction with use of a diaphragm
- Oral, injectable, or implanted contraceptives
- Tubal ligation or vasectomy (surgical sterilization)
-
-
Subjects with recent history of inadequate bone marrow reserve as demonstrated by previous transfusions except for acute blood loss (e.g. surgery) in the month prior to screening
-
Alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN)
-
Modification of diet in renal disease (MDRD) calculated glomerular filtration rate (GFR) < 30 mL/min
-
Subjects with active uncontrolled infection or who are human immunodeficiency virus (HIV) positive (subjects with acute infections requiring treatment should delay screening/enrollment until the course of therapy has been completed and the event is considered controlled)
-
Subjects with an invasive malignancy over the previous 2 years except treated basal or squamous carcinomas of the skin completely resected intraepithelial carcinoma of the cervix and completely resected papillary thyroid and follicular thyroid cancers; other completely resected cancers greater than 2 years may be considered after review by the principal investigator (PI)
-
Subjects with clinically significant uncontrolled cardiac disease
-
Subjects being treated concurrently with any prohibited medications, including investigational medication, rifampin, St. John's wort, and potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors (excluding ketoconazole) unless continuation of such medications are determined by the investigator to be in the best interest of the patient
-
Subjects who have previously received JAK inhibitor therapy
-
Subjects with active alcohol or drug addiction that would interfere with their ability to comply with the study requirements
-
Subjects with any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the subject or compliance with the protocol
-
Subjects who have unknown transfusion history for at least the 12 weeks prior to screening
-
Subjects who are unable to complete the symptom diary
-
Subjects who will need conventional therapy during the course of the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Supportive care (ruxolitinib phosphate) Ruxolitinib Phosphate Patients receive ruxolitinib phosphate PO BID (approximately 12 hours apart) for up to 2 years in the absence of disease progression or unacceptable toxicity. Supportive care (ruxolitinib phosphate) Questionnaire Administration Patients receive ruxolitinib phosphate PO BID (approximately 12 hours apart) for up to 2 years in the absence of disease progression or unacceptable toxicity.
- Primary Outcome Measures
Name Time Method Change in fatigue Baseline to 3 months As measured by the Brief Fatigue Inventory (BFI) question 3 regarding the worst fatigue in the past 24 hours. Will be analyzed in a continuous fashion.
- Secondary Outcome Measures
Name Time Method Proportion of patients with 2 point reductions in the BFI #3 score Up to 3 months Proportion of patients at 3 months versus at enrollment tabulated.
20% improvement in symptoms Up to 3 months As measured by the M. D. Anderson Symptom Inventory (MDASI).
Trial Locations
- Locations (1)
M D Anderson Cancer Center
🇺🇸Houston, Texas, United States